- Molnupiravir is effective against all major coronavirus variants and is likely to stay so.
- With winter approaching, the pandemic in America is at a critical juncture.
- However, in the next months, researchers may look into using a mix of antiviral therapies to combat the coronavirus, particularly in immunocompromised patients, where the virus commonly stays, giving it time and chance to produce mutations.
- The greatest thing would be a tablet that patients could take at home, soon after infection, to stop the biological cascade that would otherwise drive them to the hospital, the intensive care unit, or worse.
Emory University researchers published a report in March 2020 about a chemical named NHC/EIDD-2801, according to the researchers it possessed “potency against several coronaviruses,” and might become “an effective antiviral against SARS-CoV-2”, as reported by The New Yorker.
Licensed molnupiravir
Emory licensed the molecule to Ridgeback Biotherapeutics, a Miami-based biotechnology company that had previously developed a monoclonal antibody for Ebola.
Ridgeback partnered with the pharmaceutical giant Merck to accelerate its development.
The Emory researchers named their drug molnupiravir, after Mjölnir—the hammer of Thor.
It turns out that this was not hyperbole.
Last month, Merck and Ridgeback announced that molnupiravir could reduce by half the chances that a person infected by the coronavirus would need to be hospitalized.
On November 4th, the U.K. became the first country to approve molnupiravir; many observers expect that an emergency-use authorization will come from the U.S. Food and Drug Administration in December.
COVID treatment
Oral antivirals like molnupiravir have the potential to revolutionise the treatment of covid-19 and the pandemic in general.
People are frequently too sick to get numerous benefits by the time they are able to arrange a visit.
Molnupiravir, on the other hand, is a small orange pill.
Merck is presently testing whether molnupiravir can prevent infection after exposure as well as hospitalisation following infection.
If that’s the case, the medicine might be used as a preventative measure—you could be given a prescription even if you haven’t tested positive.
Molnupiravir is effective against all major coronavirus variants and is likely to stay so. In fact, it acts against a variety of RNA viruses other than sars-CoV-2 in the lab, including Ebola, hepatitis C, RSV, and norovirus.
The spike protein can change over time, but the replication machinery is essentially fixed, making it difficult for the virus to evolve resistance.
Molnupiravir breaks down into a molecule called NHC once it enters the body.
Some have speculated that a medicine that is so good at tampering with viral RNA would also mess with human DNA.
Women who were pregnant or lactating were excluded from Merck’s study, and women of reproductive age had to be on contraception.
Antiviral medications that cause genetic mistakes have long been a source of worry.
Molnupiravir, according to a recent study, does not relate directly to real-world application because the study was conducted in cells rather than living animals or humans.
Meanwhile, Merck has conducted a series of testing, both in the lab and in animal models, and found no evidence that molnupiravir produces harmful mutations at the doses and durations that would be recommended.
Infection in winter
With winter approaching, the pandemic in America is at a critical juncture.
Covid-19 has infected nearly 50,000 people in the United States.
When a virus enters our cells, its RNA is translated into proteins that carry out the virus’s tasks.
Proteins, on the other hand, start out as lengthy strings called polypeptides, which are then sliced into fragments by an enzyme called protease and assembled into proteins.
However, in the next months, researchers may look into using a mix of antiviral therapies to combat the coronavirus, particularly in immunocompromised patients, where the virus commonly stays, giving it time and chance to produce mutations.
Medication
Molnupiravir will be produced in large quantities by Merck.
The Food and Drug Administration could approve molnupiravir and Paxlovid within weeks.
He wakes up with a headache on Tuesday and develops a fever later that afternoon.
As a result, a full course of molnupiravir in underdeveloped nations could cost as little as $20, compared to roughly $700 in the United States. Paul Schaper, Merck’s senior director of global pharmaceutical strategy, told me, “Our goal was to offer this medicine to high-, middle-, and low-income nations at roughly the same time.”
As a doctor caring for covid patients last spring, I was frequently disappointed by how little we had to offer.
The greatest thing, I reasoned, would be a tablet that patients could take at home, soon after infection, to stop the biological cascade that would otherwise drive them to the hospital, the intensive care unit, or worse.
Not one, but two such treatments will be available soon.
The new antiviral medications represent the most major pharmacologic development of the epidemic, aside from vaccines.
These medications will accomplish just that, decreasing the amount of damage the coronavirus can cause and possibly closing off pathways for it to spread.
Nonetheless, ensuring that they are used meaningfully and equitably will necessitate strength in areas where the United States has struggled, such as early and accessible testing, communication and coordination among healthcare providers, fighting misinformation, and building trust in rapid scientific advances.
Antivirals cannot work without pills in individuals, just as vaccinations cannot work without needles in arms.
Did you subscribe to our newsletter?
It’s free! Click here to subscribe!
Source: The New Yorker
